Summit Therapeutics Reports Q1 2026 Financial Results and Clinical Updates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2026
0mins
Should l Buy SMMT?
Source: Newsfilter
- Clinical Trial Progress: Summit Therapeutics' ivonescimab has been administered to over 4,000 patients in clinical trials globally, with more than 70,000 patients treated in the commercial setting in China, indicating significant potential for the drug in the non-small cell lung cancer (NSCLC) market.
- Financial Position: As of March 31, 2026, the company's cash and cash equivalents stood at $598.7 million, down from $713.4 million on December 31, 2025, reflecting ongoing investments in research and development and operational expenditures.
- Increased R&D Expenses: GAAP R&D expenses for Q1 2026 reached $132.6 million, a substantial increase from $51.2 million in the same period last year, primarily driven by the expansion of clinical trials and increased stock-based compensation expenses related to ivonescimab.
- Future Outlook: Summit plans to submit a Biologics License Application (BLA) for ivonescimab to the FDA by November 14, 2026, aiming for approval to treat patients with EGFR-mutated non-small cell lung cancer, marking a significant milestone in the company's oncology portfolio.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SMMT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SMMT
Wall Street analysts forecast SMMT stock price to rise
12 Analyst Rating
8 Buy
3 Hold
1 Sell
Moderate Buy
Current: 18.080
Low
18.00
Averages
42.49
High
131.90
Current: 18.080
Low
18.00
Averages
42.49
High
131.90
About SMMT
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation into Summit Therapeutics by Johnson Fistel
- Investigation Background: Johnson Fistel, PLLP is investigating Summit Therapeutics Inc. (NASDAQ: SMMT) to determine if its executives violated federal securities laws, potentially allowing for recovery of investor losses.
- Financial Disclosure: On April 30, 2026, Summit reported its Q1 2026 financial results and updated on the HARMONi-3 Phase III clinical trial, revealing a significantly higher statistical significance threshold for the interim progression-free survival analysis than previously anticipated.
- Stock Price Impact: Following this disclosure, Summit's stock price sharply declined, resulting in investor losses and prompting Johnson Fistel to investigate compliance with federal securities laws.
- Law Firm Background: Johnson Fistel is a nationally recognized shareholder rights law firm, ranked among the Top 10 Plaintiff Law Firms in 2024, having recovered approximately $90.725 million for clients, demonstrating its effectiveness in advocating for investor rights.
See More
Summit Reports Q1 2026 Net Loss Exceeding Expectations
- Poor Financial Performance: Summit reported a net loss of $189.4 million for Q1 2026, more than tripling the $62.9 million loss from the previous year, indicating significant pressure from increased spending on its lead asset, ivonescimab, for non-small cell lung cancer treatment.
- Price Target Downgrade: Piper Sandler lowered its price target on Summit shares from $17 to $16 while maintaining a ‘Neutral’ rating, reflecting market concerns regarding the company's financial health and clinical trial outcomes.
- HARMONi-3 Trial Update: Although final data from the HARMONi-3 trial is expected in the second half of 2026, the interim analysis did not meet the high statistical bar for early success, leading to investor skepticism about the trial's prospects.
- Market Sentiment Shift: Despite a 25% drop in Summit's stock price following the report, retail sentiment on Stocktwits shifted from ‘bearish’ to ‘bullish’, indicating some investors' optimism for a potential rebound in the stock price.
See More
Summit Therapeutics' Clinical Trial Update
- Trial Continuation: Summit Therapeutics announced that its HARMONi-3 trial for ivonescimab, developed with Chinese biotech Akeso, will continue as planned following an uneventful interim analysis, despite a ~22% drop in stock price on Friday.
- Trial Design and Goals: The Phase 3 global trial aims to evaluate ivonescimab in combination with chemotherapy as a first-line treatment for metastatic non-small cell lung cancer, with early progression-free survival (PFS) analysis expected to support regulatory discussions ahead of final results scheduled for H2 2026.
- Mixed Analyst Reactions: Barclays analyst Etzer Darout noted that the interim PFS analysis was an important catalyst investors were looking forward to, but the new guidance pressured shares, maintaining an Equal Weight rating with an $18 target on SMMT.
- Price Target Adjustment: Jefferies analyst Faisal Khurshid trimmed his price target on Summit from $18 to $17 per share due to the interim PFS missing expectations, reflecting concerns about the trial's probability of success.
See More
Summit Therapeutics Reports Wider Q1 Loss and Clinical Progress
- Wider Financial Loss: Summit Therapeutics reported a net loss of $189.4 million for Q1 2026, translating to a loss of $0.24 per share, which is a significant increase from the previous year's loss of $62.9 million or $0.09 per share, indicating heightened financial pressures on the company.
- Increased Adjusted Loss: The adjusted net loss expanded to $116.6 million or $0.15 per share, compared to $51.8 million or $0.07 per share in the prior year, reflecting ongoing increases in R&D expenditures and operational costs that could impact future profitability.
- Clinical Collaboration Progress: In January 2026, Summit announced a clinical collaboration with GSK plc to evaluate Ivonescimab in combination with GSK's novel B7-H3, with patient dosing expected to begin in mid-2026, marking a strategic expansion in its oncology treatment portfolio.
- Ongoing Global Trials: The company's global Phase III trials, including HARMONi-3, HARMONi-7, and HARMONi-GI3, continue to enroll patients, with final Progression-Free Survival data from the HARMONi-3 trial expected in the second half of 2026, demonstrating its commitment to advancing clinical research.
See More
Summit Therapeutics Q1 Earnings Beat Expectations
- Earnings Performance: Summit Therapeutics reported a Q1 GAAP EPS of -$0.24, beating expectations by $0.04, indicating some financial resilience despite still being in a loss position.
- Cash Reserve Status: As of March 31, 2026, the company's cash and cash equivalents and short-term investments totaled $598.7 million, down from $713.4 million on December 31, 2025, reflecting urgency in fund utilization and potential future financing needs.
- Clinical Progress Plans: Summit Therapeutics plans an interim PFS analysis for the HARMONi-3 squamous cohort in Q2 2026, indicating proactive advancements in its clinical pipeline that may lay the groundwork for future product launches.
- Market Reaction Analysis: Despite the earnings beat, market sentiment remains cautious regarding the company's growth prospects, reflecting a complex outlook on the biopharmaceutical sector that could influence stock price volatility.
See More
Summit Therapeutics Reports Q1 2026 Financial Results and Clinical Updates
- Clinical Trial Progress: Summit Therapeutics' ivonescimab has been administered to over 4,000 patients in clinical trials globally, with more than 70,000 patients treated in the commercial setting in China, indicating significant potential for the drug in the non-small cell lung cancer (NSCLC) market.
- Financial Position: As of March 31, 2026, the company's cash and cash equivalents stood at $598.7 million, down from $713.4 million on December 31, 2025, reflecting ongoing investments in research and development and operational expenditures.
- Increased R&D Expenses: GAAP R&D expenses for Q1 2026 reached $132.6 million, a substantial increase from $51.2 million in the same period last year, primarily driven by the expansion of clinical trials and increased stock-based compensation expenses related to ivonescimab.
- Future Outlook: Summit plans to submit a Biologics License Application (BLA) for ivonescimab to the FDA by November 14, 2026, aiming for approval to treat patients with EGFR-mutated non-small cell lung cancer, marking a significant milestone in the company's oncology portfolio.
See More
Investigation into Summit Therapeutics by Johnson Fistel
- Investigation Background: Johnson Fistel, PLLP is investigating Summit Therapeutics Inc. (NASDAQ: SMMT) to determine if its executives violated federal securities laws, potentially allowing for recovery of investor losses.
- Financial Disclosure: On April 30, 2026, Summit reported its Q1 2026 financial results and updated on the HARMONi-3 Phase III clinical trial, revealing a significantly higher statistical significance threshold for the interim progression-free survival analysis than previously anticipated.
- Stock Price Impact: Following this disclosure, Summit's stock price sharply declined, resulting in investor losses and prompting Johnson Fistel to investigate compliance with federal securities laws.
- Law Firm Background: Johnson Fistel is a nationally recognized shareholder rights law firm, ranked among the Top 10 Plaintiff Law Firms in 2024, having recovered approximately $90.725 million for clients, demonstrating its effectiveness in advocating for investor rights.
See More
Summit Reports Q1 2026 Net Loss Exceeding Expectations
- Poor Financial Performance: Summit reported a net loss of $189.4 million for Q1 2026, more than tripling the $62.9 million loss from the previous year, indicating significant pressure from increased spending on its lead asset, ivonescimab, for non-small cell lung cancer treatment.
- Price Target Downgrade: Piper Sandler lowered its price target on Summit shares from $17 to $16 while maintaining a ‘Neutral’ rating, reflecting market concerns regarding the company's financial health and clinical trial outcomes.
- HARMONi-3 Trial Update: Although final data from the HARMONi-3 trial is expected in the second half of 2026, the interim analysis did not meet the high statistical bar for early success, leading to investor skepticism about the trial's prospects.
- Market Sentiment Shift: Despite a 25% drop in Summit's stock price following the report, retail sentiment on Stocktwits shifted from ‘bearish’ to ‘bullish’, indicating some investors' optimism for a potential rebound in the stock price.
See More
Summit Therapeutics' Clinical Trial Update
- Trial Continuation: Summit Therapeutics announced that its HARMONi-3 trial for ivonescimab, developed with Chinese biotech Akeso, will continue as planned following an uneventful interim analysis, despite a ~22% drop in stock price on Friday.
- Trial Design and Goals: The Phase 3 global trial aims to evaluate ivonescimab in combination with chemotherapy as a first-line treatment for metastatic non-small cell lung cancer, with early progression-free survival (PFS) analysis expected to support regulatory discussions ahead of final results scheduled for H2 2026.
- Mixed Analyst Reactions: Barclays analyst Etzer Darout noted that the interim PFS analysis was an important catalyst investors were looking forward to, but the new guidance pressured shares, maintaining an Equal Weight rating with an $18 target on SMMT.
- Price Target Adjustment: Jefferies analyst Faisal Khurshid trimmed his price target on Summit from $18 to $17 per share due to the interim PFS missing expectations, reflecting concerns about the trial's probability of success.
See More
Summit Therapeutics Reports Wider Q1 Loss and Clinical Progress
- Wider Financial Loss: Summit Therapeutics reported a net loss of $189.4 million for Q1 2026, translating to a loss of $0.24 per share, which is a significant increase from the previous year's loss of $62.9 million or $0.09 per share, indicating heightened financial pressures on the company.
- Increased Adjusted Loss: The adjusted net loss expanded to $116.6 million or $0.15 per share, compared to $51.8 million or $0.07 per share in the prior year, reflecting ongoing increases in R&D expenditures and operational costs that could impact future profitability.
- Clinical Collaboration Progress: In January 2026, Summit announced a clinical collaboration with GSK plc to evaluate Ivonescimab in combination with GSK's novel B7-H3, with patient dosing expected to begin in mid-2026, marking a strategic expansion in its oncology treatment portfolio.
- Ongoing Global Trials: The company's global Phase III trials, including HARMONi-3, HARMONi-7, and HARMONi-GI3, continue to enroll patients, with final Progression-Free Survival data from the HARMONi-3 trial expected in the second half of 2026, demonstrating its commitment to advancing clinical research.
See More
Summit Therapeutics Q1 Earnings Beat Expectations
- Earnings Performance: Summit Therapeutics reported a Q1 GAAP EPS of -$0.24, beating expectations by $0.04, indicating some financial resilience despite still being in a loss position.
- Cash Reserve Status: As of March 31, 2026, the company's cash and cash equivalents and short-term investments totaled $598.7 million, down from $713.4 million on December 31, 2025, reflecting urgency in fund utilization and potential future financing needs.
- Clinical Progress Plans: Summit Therapeutics plans an interim PFS analysis for the HARMONi-3 squamous cohort in Q2 2026, indicating proactive advancements in its clinical pipeline that may lay the groundwork for future product launches.
- Market Reaction Analysis: Despite the earnings beat, market sentiment remains cautious regarding the company's growth prospects, reflecting a complex outlook on the biopharmaceutical sector that could influence stock price volatility.
See More
Summit Therapeutics Reports Q1 2026 Financial Results and Clinical Updates
- Clinical Trial Progress: Summit Therapeutics' ivonescimab has been administered to over 4,000 patients in clinical trials globally, with more than 70,000 patients treated in the commercial setting in China, indicating significant potential for the drug in the non-small cell lung cancer (NSCLC) market.
- Financial Position: As of March 31, 2026, the company's cash and cash equivalents stood at $598.7 million, down from $713.4 million on December 31, 2025, reflecting ongoing investments in research and development and operational expenditures.
- Increased R&D Expenses: GAAP R&D expenses for Q1 2026 reached $132.6 million, a substantial increase from $51.2 million in the same period last year, primarily driven by the expansion of clinical trials and increased stock-based compensation expenses related to ivonescimab.
- Future Outlook: Summit plans to submit a Biologics License Application (BLA) for ivonescimab to the FDA by November 14, 2026, aiming for approval to treat patients with EGFR-mutated non-small cell lung cancer, marking a significant milestone in the company's oncology portfolio.
See More
